UNSPSC 51181606: Propylthiouracil

This classification denotes an antithyroid agent with the molecular formula C7H10N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 721M9407IY, chemically known as 2,3-dihydro-6-propyl-2-thioxo-4(1h)-pyrimidinone but generally known as propylthiouracil, which bears US NIH Compound Identifier 657298. European Medicines Agency schedules Propylthiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10123MIG. The term PROPYLTHIOURACIL is an International Non-Proprietary Name.

UNSPSC 51181606 Propylthiouracil (Commodity) covers a thyroid-function pharmaceutical that state and local governments procure through cooperative purchasing vehicles and multi-source generic drug programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicited this commodity as part of a broader RFP for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. State and local procurement under this code reflects centralized pharmaceutical sourcing through cooperative agreements rather than individual agency buys; vendors supply products through authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) and must maintain cGMP certification, Drug Supply Chain Security Act compliance, contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, and comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. The MMCAP RFP weights evaluation heavily on price competitiveness (75 percent) with secondary weight on fixed pricing (10 percent), compliance with administrative data-format requirements (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent); vendors must submit National Drug Code (NDC) numbers, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations.

MMCAP activity centered on Minnesota with participating members in Oregon; the RFP issued January 20, 2026, with proposal due date of March 26, 2026. Contract awards will take effect July 1, 2026, for a two-year initial term with optional MMCAP extensions or alignment with incumbent expiration dates through June 30, 2028. Vendors must ensure product availability by May 15, 2026, and comply with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials; all products require FDA compliance and minimum expiration dates of at least one year from manufacture with a six-month shelf life guarantee.